Deutsche Bank
AMLX icon

Deutsche Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Deutsche Bank’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6M Sell
1,267,785
-65,451
-5% -$921K 0.01% 891
2025
Q4 		$16.1M Sell
1,333,236
-32,285
-2% -$439K 0.01% 935
2025
Q3 		$18.6M Buy
1,365,521
+748,602
+121% +$7.05M 0.01% 877
2025
Q2 		$3.95M Buy
616,919
+46,062
+8% +$224K ﹤0.01% 1343
2025
Q1 		$2.02M Hold
570,857
– – ﹤0.01% 1741
2024
Q4 		$2.16M Hold
570,857
– – ﹤0.01% 1805
2024
Q3 		$1.85M Hold
570,857
– – ﹤0.01% 1798
2024
Q2 		$1.08M Sell
570,857
-185,312
-25% -$359K ﹤0.01% 1948
2024
Q1 		$2.15M Sell
756,169
-96,831
-11% -$1.27M ﹤0.01% 1628
2023
Q4 		$12.6M Buy
853,000
+828,584
+3,394% +$12.7M 0.01% 923
2023
Q3 		$447K Sell
24,416
-167,195
-87% -$3.54M ﹤0.01% 2238
2023
Q2 		$4.13M Buy
191,611
+160,291
+512% +$4.33M ﹤0.01% 1307
2023
Q1 		$919K Buy
31,320
+9,359
+43% +$325K ﹤0.01% 2155
2022
Q4 		$811K Buy
21,961
+6,977
+47% +$248K ﹤0.01% 2173
2022
Q3 		$422K Buy
14,984
+10,292
+219% +$257K ﹤0.01% 2469
2022
Q2 		$90K Sell
4,692
-657
-12% -$7.8K ﹤0.01% 3564
2022
Q1 		$69K Buy
+5,349
New +$121K ﹤0.01% 3721

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank's AMLX Position: Q1 2026 in Review

Deutsche Bank reduced its Amylyx Pharmaceuticals (AMLX) stake by 4.9% in Q1 2026, selling an estimated $921K and leaving 1,267,785 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #891.

Deutsche Bank first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $18.6M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Deutsche Bank held 1,267,785 shares of Amylyx Pharmaceuticals worth $17.6M as of Q1 2026.
  • Deutsche Bank sold 65,451 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $921K.
  • Amylyx Pharmaceuticals made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #891 holding.
  • Deutsche Bank first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Deutsche Bank's Amylyx Pharmaceuticals position peaked at $18.6M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.